Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials.

about

Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials.

Item

http://www.wikidata.org/entity/Q50166015

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Efficacy and safety of B-cell ...... of randomized clinical trials.

@en

Efficacy and safety of B-cell ...... of randomized clinical trials.

@nl

type

Item

label

Efficacy and safety of B-cell ...... of randomized clinical trials.

@en

Efficacy and safety of B-cell ...... of randomized clinical trials.

@nl

prefLabel

Efficacy and safety of B-cell ...... of randomized clinical trials.

@en

Efficacy and safety of B-cell ...... of randomized clinical trials.

@nl

P1476

Efficacy and safety of B-cell ...... of randomized clinical trials

@en

P2093

Anna Puła

http://www.w3.org/2001/XMLSchema#string

Elżbieta Iskierka-Jażdżewska

http://www.w3.org/2001/XMLSchema#string

Tadeusz Robak

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Reproducible Research in Computational Science

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953-2012: a systematic analysis of population-based data

Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.

Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia.

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.

P304

1084-1094

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1080/10428194.2017.1375101

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Konrad Stawiski

Marcin Braun

P577

2017-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28891366

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte